Agios Pharmaceuticals (NASDAQ:AGIO) is set to announce its earnings results before the market opens on Wednesday, February 14th. Analysts expect the company to announce earnings of ($1.65) per share for the quarter.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at $73.11 on Monday. The firm has a market capitalization of $3,560.00, a PE ratio of -11.66 and a beta of 2.12. Agios Pharmaceuticals has a 12 month low of $45.11 and a 12 month high of $82.96.

Several analysts recently weighed in on AGIO shares. Credit Suisse Group raised their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Oppenheimer set a $83.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 17th. SunTrust Banks set a $80.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Finally, Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $77.64.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 23,572 shares of the stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $81.09, for a total value of $1,911,453.48. Following the completion of the transaction, the chief executive officer now directly owns 23,572 shares in the company, valued at $1,911,453.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 3,838 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $59.37, for a total value of $227,862.06. Following the completion of the transaction, the director now owns 80,851 shares of the company’s stock, valued at $4,800,123.87. The disclosure for this sale can be found here. Insiders sold 187,114 shares of company stock valued at $14,109,545 over the last quarter. Corporate insiders own 5.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Wednesday” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://theolympiareport.com/2018/02/12/agios-pharmaceuticals-agio-scheduled-to-post-earnings-on-wednesday.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.